ID
30874
Beschrijving
This ODM file contains documentation of Serious Adverse Events. To be checked for (and added if neccessary) at Sessions 1 and 2 (Day -1), Early Withdrawal and Follow-Up. Study ID: 109710 Clinical Study ID: DAN109710 Study Title: A single-blind, randomized, placebo controlled, two-period crossover fMRI study to investigate the effects of the D3 antagonist GSK598809 on neural and behavioural responses to food reward and reinforcement after a single oral dose of GSK598809 in overweight and obese subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01039454 https://clinicaltrials.gov/ct2/show/NCT01039454 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: GSK598809 Trade Name: Study Indication: Substance Dependence Brief Summary: This novel compound is a new experimental treatment that may help people to stop compulsive overeating. Compulsive overeating or binge eating is one of the main reasons why people are overweight or obese. Recent research has shown that some kinds of overeating may be linked to a brain chemical called dopamine. There is some evidence that blocking the action of this chemical in animals can reduce food intake, particularly of foods that are high in fat and sugar. The purpose of this study is to find out if this compound (which blocks the effects of dopamine) has the same effect in overweight or obese people, as it does in animals.
Link
https://clinicaltrials.gov/ct2/show/NCT01039454
Trefwoorden
Versies (1)
- 29-06-18 29-06-18 - Sarah Riepenhausen
Houder van rechten
GlaxoSmithKline
Geüploaded op
29 juni 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Effects of D3 antagonist GSK598809 on neural and behavioural responses to food reward/reinforcement after a single dose in overweight/obese subjects NCT01039454
Serious Adverse Events
- StudyEvent: ODM
Beschrijving
Serious Adverse Events - Section 1
Alias
- UMLS CUI-1
- C1519255
Beschrijving
If Yes, record details below. A serious adverse event is any untoward medical occurrence that, at any dose: a) results in death. b) is life-threatening: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe. c) requires hospitalisation or prolongation of existing hospitalisation: In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or out-patient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is ’serious’. When in doubt as to whether ’hospitalisation’ occurred or was necessary, the AE should be considered ’serious’. Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE. d) results in disability/incapacity: The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption. e) is a congenital anomaly/birth defect. f) other. Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse.
Datatype
text
Alias
- UMLS CUI [1]
- C1519255
Beschrijving
Ensure that no medical or investigational procedures are captured on Non-Serious Adverse Events pages. Death should not be recorded as an SAE but should be recorded as the outcome of an SAE. The condition that resulted in the death should be recorded as the SAE. Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE. However, if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page. If this was recorded previously as a non-serious event but has progressed to serious, put a line through the Non-Serious AE record and transcribe the details onto the SAE form.
Datatype
text
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0011900
Beschrijving
Start dates must be provided for the reporting of adverse event data. If the exact date is not known, liaise with the investigator to ensure that a best estimate is provided.
Datatype
date
Alias
- UMLS CUI [1,1]
- C2697888
- UMLS CUI [1,2]
- C1519255
Beschrijving
Start Time Serious Adverse Event
Datatype
time
Alias
- UMLS CUI [1,1]
- C2697889
- UMLS CUI [1,2]
- C1519255
Beschrijving
Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = Those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).
Datatype
text
Alias
- UMLS CUI [1,1]
- C0518690
- UMLS CUI [1,2]
- C1519255
Beschrijving
All SAEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the SAE was ongoing at the time of death, but was not the cause of death, enter fatal for the SAE which was the direct cause of death.
Datatype
integer
Alias
- UMLS CUI [1,1]
- C1705586
- UMLS CUI [1,2]
- C1519255
Beschrijving
Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was temporarily interrupted but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing) or the subject died and there was no prior decision to discontinue IP(s).
Datatype
text
Alias
- UMLS CUI [1,1]
- C1704758
- UMLS CUI [1,2]
- C1519255
Beschrijving
This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died. If the event Recovered/ Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the SAE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.
Datatype
date
Alias
- UMLS CUI [1,1]
- C2697886
- UMLS CUI [1,2]
- C1519255
Beschrijving
Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’. If the subject was withdrawn from the study due to an SAE, confirm that the following variables are consistent for the adverse event which resulted in withdrawal: If investigational product was permanently withdrawn due to an adverse event: ‘Primary Reason for Withdrawal’ on the Study Conclusion page is recorded as ‘Adverse Event’ If the subject was withdrawn from the study for an adverse event: ‘Withdrawal’ on the Serious Adverse Events page is recorded as ‘Yes’, ‘Action Taken with Investigational Product(s) as a Result of the SAE’ on the Non-Serious Adverse Events page is recorded as ‘Investigational Product Withdrawn’.
Datatype
text
Alias
- UMLS CUI [1,1]
- C1710677
- UMLS CUI [1,2]
- C1519255
Beschrijving
End Time Serious Adverse Event
Datatype
time
Alias
- UMLS CUI [1,1]
- C2826658
- UMLS CUI [1,2]
- C1519255
Beschrijving
It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.
Datatype
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0085978
- UMLS CUI [1,3]
- C1519255
Beschrijving
Intermittent should be used if the subject experiences the same AE on multiple occasions over a period of time (e.g., dizziness). In these circumstances, the start date will be the start date of the first episode and the end date will be the date of resolution.
Datatype
integer
Alias
- UMLS CUI [1,1]
- C1518404
- UMLS CUI [1,2]
- C0439603
Beschrijving
If Yes, summarise findings in Section 11 Narrative Remarks of this SAE form.
Datatype
text
Alias
- UMLS CUI [1,1]
- C0004398
- UMLS CUI [1,2]
- C1519255
Beschrijving
Serious Adverse Events - Section 2: Seriousness
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C0439793
Beschrijving
Serious Adverse Event resulting in Death
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C1705232
Beschrijving
Life-threatening Serious Adverse Event
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1517874
- UMLS CUI [1,2]
- C1519255
Beschrijving
Serious Adverse Event requiring hospitalisation (prolongation)
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0019993
Beschrijving
Serious adverse event resulting in disability
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0231170
Beschrijving
Serious Adverse Event: congenital anomaly/birth defect
Datatype
boolean
Alias
- UMLS CUI [1]
- C2826727
Beschrijving
Serious Adverse Event, other reason for seriousness
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C3840932
Beschrijving
Serious Adverse Event, other reason for seriousness
Datatype
text
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C3840932
Beschrijving
Serious Adverse Events - Section 3: Demography Data
Alias
- UMLS CUI-1
- C1828479
- UMLS CUI-2
- C0011298
- UMLS CUI-3
- C1519255
Beschrijving
Serious Adverse Events - Section 4: Recurrence
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C0034897
Beschrijving
If deliberate or inadvertent administration of further dose(s) of investigational product(s) to the subject occurred, did the reported adverse event recur?
Datatype
text
Alias
- UMLS CUI [1,1]
- C2945760
- UMLS CUI [1,2]
- C1519255
Beschrijving
Serious Adverse Events - Section 5: Possible Causes Of SAE Other Than Investigational Products
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C0015127
Beschrijving
Cause of Serious Adverse Event: Disease under Study
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0008976
- UMLS CUI [1,4]
- C0012634
Beschrijving
Cause of Serious Adverse Event: Medical Condition
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0012634
Beschrijving
Cause of Serious Adverse Event: Medical Condition
Datatype
text
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0012634
Beschrijving
Cause of Serious Adverse Event: Lack of Efficacy
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0235828
Beschrijving
Cause of Serious Adverse Event: Withdrawal of Investigational Products
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C2349954
- UMLS CUI [1,4]
- C0013227
Beschrijving
Cause of Serious Adverse Event: Concomitant Medications
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C2347852
- UMLS CUI [1,2]
- C1519255
- UMLS CUI [1,3]
- C1547657
Beschrijving
Cause of Serious Adverse Event: Concomitant Medications
Datatype
text
Alias
- UMLS CUI [1,1]
- C2347852
- UMLS CUI [1,2]
- C1519255
- UMLS CUI [1,3]
- C1547657
Beschrijving
Cause of Serious Adverse Event: Activity related to study participation (e.g., procedures)
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C2348568
Beschrijving
Other Cause of Serious Adverse Event
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0205394
Beschrijving
Other Cause of Serious Adverse Event
Datatype
text
Alias
- UMLS CUI [1,1]
- C1547657
- UMLS CUI [1,2]
- C0877248
- UMLS CUI [1,3]
- C0205394
Beschrijving
Serious Adverse Events - Section 6: Relevant medical conditions
Beschrijving
Serious Adverse Event: Medical Disorder, Allergy, Surgery
Datatype
text
Alias
- UMLS CUI [1]
- C0020517
- UMLS CUI [2]
- C0543467
- UMLS CUI [3]
- C0009488
Beschrijving
Date of Onset
Datatype
date
Alias
- UMLS CUI [1,1]
- C0574845
- UMLS CUI [1,2]
- C0009488
- UMLS CUI [2,1]
- C0574845
- UMLS CUI [2,2]
- C0020517
- UMLS CUI [3,1]
- C0574845
- UMLS CUI [3,2]
- C0543467
Beschrijving
Present at Serious Adverse Event
Datatype
text
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C0348080
- UMLS CUI [1,3]
- C0150312
Beschrijving
Date of last occurence
Datatype
date
Alias
- UMLS CUI [1,1]
- C0012634
- UMLS CUI [1,2]
- C0011008
- UMLS CUI [1,3]
- C2745955
Beschrijving
Serious Adverse Events - Section 7: Other relevant risk factors
Alias
- UMLS CUI-1
- C0035648
- UMLS CUI-2
- C1519255
Beschrijving
Serious Adverse Events - Section 8: Relevant concomitant medication
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C2347852
Beschrijving
Include details of any concomitant medication(s) which may have contributed to the event. Trade name preferred.
Datatype
text
Alias
- UMLS CUI [1,1]
- C2360065
- UMLS CUI [1,2]
- C2347852
- UMLS CUI [1,3]
- C1519255
Beschrijving
Dose
Datatype
float
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C2826767
Beschrijving
Unit
Datatype
text
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C2826646
Beschrijving
Frequency
Datatype
text
Alias
- UMLS CUI [1,1]
- C1519255
- UMLS CUI [1,2]
- C2826654
Beschrijving
Route
Datatype
text
Alias
- UMLS CUI [1,1]
- C2826730
- UMLS CUI [1,2]
- C1519255
Beschrijving
Taken prior to study?
Datatype
text
Alias
- UMLS CUI [1,1]
- C2826667
- UMLS CUI [1,2]
- C1519255
Beschrijving
Start Date
Datatype
date
Alias
- UMLS CUI [1,1]
- C2826734
- UMLS CUI [1,2]
- C1519255
Beschrijving
Stop Date
Datatype
date
Alias
- UMLS CUI [1,1]
- C0806020
- UMLS CUI [1,2]
- C2347852
Beschrijving
Ongoing medication?
Datatype
text
Alias
- UMLS CUI [1,1]
- C2826666
- UMLS CUI [1,2]
- C1519255
Beschrijving
Reason for medication
Datatype
text
Alias
- UMLS CUI [1,1]
- C2826696
- UMLS CUI [1,2]
- C1519255
Beschrijving
Serious Adverse Events - Section 9: Details of investigational Products
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C0304229
Beschrijving
Complete this section using the information in the Investigational Product page. Details of all investigational product(s) taken until the time of the SAE should be included. Provide specific details in Section 11 Narrative Remarks if the subject has taken an overdose of investigational product(s), including whether it was accidental or intentional.
Datatype
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C1519255
Beschrijving
Treatment blind broken
Datatype
text
Alias
- UMLS CUI [1,1]
- C3897431
- UMLS CUI [1,2]
- C1519255
Beschrijving
SECTION 10: Details of RELEVANT Assessments
Alias
- UMLS CUI-1
- C1519255
- UMLS CUI-2
- C0431080
Beschrijving
Serious Adverse Events - Section 11: Narrative Remarks
Alias
- UMLS CUI-1
- C0947611
- UMLS CUI-2
- C1519255
Beschrijving
Narrative Remarks
Datatype
text
Alias
- UMLS CUI [1,1]
- C0947611
- UMLS CUI [1,2]
- C1519255
Beschrijving
confirming that the data on the SAE pages are accurate and complete
Datatype
text
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C1519255
Beschrijving
Date of Investigator signature
Datatype
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Beschrijving
Investigator's Name
Datatype
text
Alias
- UMLS CUI [1]
- C2826892
Similar models
Serious Adverse Events
- StudyEvent: ODM
C0011900 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0085978 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C0439603 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0439793 (UMLS CUI-2)
C1705232 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0019993 (UMLS CUI [1,2])
C0231170 (UMLS CUI [1,2])
C3840932 (UMLS CUI [1,2])
C3840932 (UMLS CUI [1,2])
C0011298 (UMLS CUI-2)
C1519255 (UMLS CUI-3)
C0034897 (UMLS CUI-2)
C1519255 (UMLS CUI [1,2])
C0015127 (UMLS CUI-2)
C0877248 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0012634 (UMLS CUI [1,4])
C0877248 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C0235828 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C2349954 (UMLS CUI [1,3])
C0013227 (UMLS CUI [1,4])
C1519255 (UMLS CUI [1,2])
C1547657 (UMLS CUI [1,3])
C1519255 (UMLS CUI [1,2])
C1547657 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0877248 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C0543467 (UMLS CUI [2])
C0009488 (UMLS CUI [3])
C0009488 (UMLS CUI [1,2])
C0574845 (UMLS CUI [2,1])
C0020517 (UMLS CUI [2,2])
C0574845 (UMLS CUI [3,1])
C0543467 (UMLS CUI [3,2])
C0348080 (UMLS CUI [1,2])
C0150312 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,2])
C2745955 (UMLS CUI [1,3])
C1519255 (UMLS CUI-2)
C1519255 (UMLS CUI [1,2])
C2347852 (UMLS CUI-2)
C2347852 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
C2826767 (UMLS CUI [1,2])
C2826646 (UMLS CUI [1,2])
C2826654 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0304229 (UMLS CUI-2)
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0431080 (UMLS CUI-2)
C0431080 (UMLS CUI [1,2])
C1519255 (UMLS CUI-2)
C1519255 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
Geen commentaren